Novartis to pay $245m to end antitrust cases on Exforge
Novartis said today it will pay $245m to end antitrust litigation accusing the Swiss drugmaker of trying to delay the launch in the US of generic versions of its Exforge hypertension drug.
Business
• 29 Dec 22
